Cipla launches Yurpeak for obesity and type 2 diabetes in India

Cipla Limited on Wednesday launched Yurpeak (tirzepatide) in India, a once-weekly injectable therapy for managing obesity and type 2 diabetes, two of the country’s most pressing health challenges. Yurpeak is

the second brand of Eli Lilly’s tirzepatide to enter the Indian market, following DCGI approval for its use.

Tirzepatide works as a dual agonist on GIP and GLP-1 receptors, and is indicated as an adjunct to diet and exercise for adults with obesity (BMI ≥ 30) or overweight individuals (BMI ≥ 27) with at least one weight-related health condition, as well as for type 2 diabetes management.

Yurpeak will be available in six strengths (2.5 mg to 15 mg) via the KwikPen device, allowing precise, patient-friendly dosing. Cipla has the rights to distribute and promote the therapy in India, while Lilly will manufacture and supply it at the same price as Mounjaro.

Achin Gupta, Global COO of Cipla, said the launch “marks a transformative moment in the fight against obesity and type 2 diabetes,” emphasising Cipla’s focus on nationwide accessibility and patient education.

The company will provide guidance on dosing, self-administration, and safe use to help patients manage their treatment responsibly. Ahead of the launch, Cipla shares closed at ₹1,490 on the NSE, down 0.04%.